Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KARS1 | Q15046 | 12/20 | 0.49 |
| ▸ | SYK | P43405 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.39 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.39 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2866315 | 1.00 | KARS1 (0.49) | KARS1SYKKDRKCNN1KCNN2 | |
| SCHEMBL2857355 | 0.86 | KARS1 (0.51) | KARS1SYKKDRKCNN1KCNN2 | |
| SCHEMBL2857352 | 0.86 | KARS1 (0.51) | KARS1SYKKDRKCNN1KCNN2 | |
| SCHEMBL13136575 | 0.85 | KARS1 (0.53) | KARS1SYKKDRJAK2MEN1 | |
| SCHEMBL13136583 | 0.85 | KARS1 (0.53) | KARS1SYKKDRKCNN1KCNN2 | |
| SCHEMBL2880107 | 0.85 | KARS1 (0.53) | KARS1SYKKDRKCNN1KCNN2 | |
| SCHEMBL13136577 | 0.83 | KARS1 (0.48) | KARS1SYKKDRKCNN1KCNN2 | |
| SCHEMBL2869562 | 0.83 | KARS1 (0.55) | KARS1SYKKDRKCNN1KCNN2 | |
| SCHEMBL13177675 | 0.82 | KARS1 (0.54) | KARS1SYKKDRKCNN1KCNN2 | |
| SCHEMBL13136552 | 0.81 | KARS1 (0.56) | KARS1SYKKDRJAK2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1854793-A1 | NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY | Japan Tobacco, Inc. (JP) | 2007-11-14 | — | — | EP | claimed |
| US-7803801-B2 | Aminopyridine compounds having Syk inhibitory activity | JAPAN TOBACCO, INC. (JP) | 2010-09-28 | — | — | US | disclosed |
| EP-1854793-A1 | NOVEL AMINOPYRIDINE COMPOUND WITH Syk INHIBITORY ACTIVITY | Japan Tobacco, Inc. (JP) | 2007-11-14 | — | — | EP | disclosed |
| US-20060205731-A1 | Novel aminopyridine compounds having Syk inhibitory activity | JAPAN TOBACCO INC. (JP) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205731-A1 | Novel aminopyridine compounds having Syk inhibitory activity | SYK, BTK, ZAP70 | KARS1 2175/4885SYK 1/4885KDR 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.